We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
Cap. Flow
+$40.7M
Cap. Flow %
1.55%
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$47.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.7M
5
PFE icon
Pfizer
PFE
+$13.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.2M
2
SYK icon
Stryker
SYK
+$24.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$24M
4
HUM icon
Humana
HUM
+$20.2M
5
UNH icon
UnitedHealth
UNH
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Real Estate 2.01%
3 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$27.5B
$28.7M 1.09%
143,214
– –
BSX icon
27
Boston Scientific
BSX
$69.5B
$28.3M 1.08%
565,990
-191,025
-25% -$9M
MDT icon
28
Medtronic
MDT
$109B
$27.8M 1.06%
344,517
+18,345
+6% +$1.5M
DHR icon
29
Danaher
DHR
$137B
$26.6M 1.01%
119,218
– –
DXCM icon
30
DexCom
DXCM
$31.5B
$26.6M 1.01%
228,747
+10,732
+5% +$1.2M
CRL icon
31
Charles River Laboratories
CRL
$11.2B
$23.8M 0.91%
118,083
+45,408
+62% +$10.3M
MCK icon
32
McKesson
MCK
$100B
$23.7M 0.9%
66,455
– –
HCA icon
33
HCA Healthcare
HCA
$87.2B
$23.4M 0.89%
88,703
-16,300
-16% -$4.14M
ZTS icon
34
Zoetis
ZTS
$32.4B
$22.8M 0.87%
136,914
– –
JAZZ icon
35
Jazz Pharmaceuticals
JAZZ
$15.9B
$21.6M 0.82%
147,779
-35,003
-19% -$5.18M
SYK icon
36
Stryker
SYK
$125B
$20.4M 0.78%
71,578
-92,550
-56% -$24.6M
HUM icon
37
Humana
HUM
$43.7B
$17.9M 0.68%
36,794
-40,919
-53% -$20.2M
NVO
38
Novo Nordisk
NVO
$208B
$17.7M 0.67%
222,646
-38,400
-15% -$2.72M
MOH icon
39
Molina Healthcare
MOH
$10.2B
$16.5M 0.63%
61,856
-11,759
-16% -$3.38M
RMD icon
40
ResMed
RMD
$30.6B
$16M 0.61%
73,189
+12,490
+21% +$2.71M
EW icon
41
Edwards Lifesciences
EW
$49.6B
$14.2M 0.54%
171,146
-242
-0.1% -$19K
EXEL icon
42
Exelixis
EXEL
$13.3B
$14.1M 0.54%
+726,639
New +$12.7M
UTHR icon
43
United Therapeutics
UTHR
$25.8B
$13.7M 0.52%
61,200
-53,877
-47% -$13.3M
ACHC icon
44
Acadia Healthcare
ACHC
$2.76B
$13.5M 0.51%
186,487
+45,298
+32% +$3.53M
ASND icon
45
Ascendis Pharma A/S
ASND
$16B
$13.3M 0.51%
123,791
– –
QURE icon
46
uniQure
QURE
$3.03B
$13.1M 0.5%
652,446
– –
DOC
47
DELISTED
PHYSICIANS REALTY TRUST
DOC
$13M 0.5%
873,655
+704,914
+418% +$10.6M
BNTX icon
48
BioNTech
BNTX
$22.9B
$12.9M 0.49%
103,858
– –
IQV icon
49
IQVIA
IQV
$38.7B
$12.6M 0.48%
63,117
– –
NVS icon
50
Novartis
NVS
$297B
$12.5M 0.48%
136,225
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
  • Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
  • Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
  • Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
  • Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
  • Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.